CRL.N Surges Past 5-Day SMA, Signaling Bullish Momentum
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 26 2025
0mins
Should l Buy CRL?
Source: Coinmarketcap
Shares of CRL.N experienced a notable uptick today, crossing above the 5-day simple moving average (SMA) for the first time in several weeks. This technical breakout suggests a shift in momentum, indicating potential bullish sentiment among investors. Analysts point to recent positive developments in the company's product pipeline as a catalyst for this upward movement. The stock's ability to surpass this key technical level could attract further buying interest, reinforcing the bullish outlook for CRL.N in the near term.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRL
Wall Street analysts forecast CRL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRL is 202.10 USD with a low forecast of 170.00 USD and a high forecast of 225.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
8 Buy
4 Hold
0 Sell
Moderate Buy
Current: 183.700
Low
170.00
Averages
202.10
High
225.00
Current: 183.700
Low
170.00
Averages
202.10
High
225.00
About CRL
Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Charles River Laboratories to Release Q4 2025 Results and 2026 Guidance on February 18
- Earnings Release Schedule: Charles River Laboratories is set to announce its Q4 and full-year 2025 financial results along with 2026 guidance on February 18, 2025, before market open, aiming to provide investors with a clear outlook for the future.
- Conference Call Details: A conference call is scheduled for February 18, 2025, at 8:30 a.m. ET to discuss the financial results and guidance, enhancing communication and transparency with investors.
- Live Webcast Opportunity: Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the company's website, ensuring timely access to key information for all stakeholders.
- Replay Access: Following the call, a replay will be available on the same website, further improving the accessibility and transparency of information for investors.
See More
Charles River Laboratories Under Investigation, Revenue Growth Expected to Decline by 400 Basis Points
- Investigation Launched: Former Louisiana Attorney General Charles C. Foti announces that Kahn Swick & Foti, LLC is investigating Charles River Laboratories for potential breaches of fiduciary duties to shareholders.
- Legal Action: Charles River and its executives are facing a securities class action lawsuit for failing to disclose material information, which could further impact the company's reputation and stock price.
- Revenue Growth Decline: The company disclosed in February 2023 that it suspended shipments of non-human primates from Cambodia due to a subpoena from the U.S. Department of Justice, leading to an expected revenue growth decline of 200 to 400 basis points, directly affecting annual financial performance.
- Compliance Risks: Kahn Swick & Foti's investigation will assess whether Charles River violated state or federal laws, and if confirmed, could lead to more severe legal consequences and financial losses.
See More
U.S. Stock Index Futures Rise as Bank Earnings Boost Market Sentiment
- Market Sentiment Rebound: U.S. stock index futures rose with S&P 500 futures up 0.42%, Nasdaq 100 futures up 0.56%, and Dow futures up 0.21%, indicating a boost in investor confidence driven by upbeat bank earnings and a tech rally.
- Treasury Yield Fluctuations: The U.S. 2-year Treasury yield fell to 3.57%, down 0.17%, while the 10-year yield edged lower to 4.17%, down 0.12%; conversely, the 30-year yield ticked up to 4.81%, adding 0.12%, reflecting mixed market expectations about future economic conditions.
- Premarket Trading Winners: In premarket trading, Ralph Lauren gained 1.74%, Baker Hughes rose 1.63%, and Robinhood Markets increased by 1.63%, indicating strong market performance that may attract further investor interest.
- Premarket Trading Losers: Conversely, Brown-Forman fell 4.33%, J.B. Hunt Transport Services dropped 4.19%, and Charles River Laboratories declined 3.13%, suggesting these companies are under market pressure, potentially impacting their short-term stock performance.
See More
Charles River Laboratories Upgraded to Overweight Rating
- Rating Upgrade: Charles River Laboratories (CRL) has received an overweight rating from analysts, reflecting market confidence in its future growth potential, which is expected to attract more investor interest.
- Market Expectations: Analysts have adjusted the average price target for CRL, indicating an optimistic outlook on the company's future performance, which could drive stock price increases and bolster investor confidence.
- Industry Position: As a key player in the biopharmaceutical sector, the upgrade in CRL's rating may enhance its competitiveness among peers, further solidifying its market leadership.
- Investor Reaction: The rating increase could lead to short-term stock price volatility, attracting more institutional investor attention, thereby increasing market liquidity and driving stock price appreciation.
See More
Charles River Laboratories Upgraded to Overweight Rating
- Rating Upgrade: Charles River Laboratories (CRL) has received an overweight rating from analysts, indicating a positive outlook for its future performance, which may drive stock price increases and attract more investor interest.
- Increased Market Confidence: The average price target for CRL has been raised by analysts, reflecting confidence in the company's continued growth in the biopharmaceutical sector, likely enhancing investor interest and trust in the firm.
- Optimistic Industry Outlook: With the rapid development of the biopharmaceutical industry, CRL, as a leading contract research organization, stands to benefit from overall industry growth, further solidifying its market position.
- Heightened Investor Attention: The rating upgrade may trigger increased attention from institutional investors, thereby enhancing CRL's market liquidity and shareholder base, promoting the company's long-term growth.
See More
Charles River Laboratories to Acquire $510M Assets and Appoint New Executive
- Acquisition Plan: Charles River Laboratories plans to acquire K.F. (Cambodia) Ltd. assets for approximately $510 million, a leading supplier of non-human primates, with the transaction expected to close in early Q1 2026, enhancing its supply capabilities in biomedical research.
- Earnings Outlook: The acquisition is projected to contribute about $0.25 to non-GAAP earnings per share in 2026 and $0.60 in 2027, despite K.F. not being expected to generate significant third-party revenue, thereby improving the company's overall profitability.
- Equity Acquisition: The company has also exercised its option to acquire the remaining 79% equity stake in PathoQuest SAS for approximately €51.6 million ($60 million), with the deal set to close by the end of Q1 2026, further solidifying its position in biopharmaceutical quality control testing.
- Executive Appointment: Charles River has appointed Namandjé Bumpus as Senior Vice President and Chief Scientific and Innovation Officer, aiming to strengthen its scientific leadership and innovation capabilities to drive future business growth.
See More
Charles River Laboratories to Release Q4 2025 Results and 2026 Guidance on February 18
- Earnings Release Schedule: Charles River Laboratories is set to announce its Q4 and full-year 2025 financial results along with 2026 guidance on February 18, 2025, before market open, aiming to provide investors with a clear outlook for the future.
- Conference Call Details: A conference call is scheduled for February 18, 2025, at 8:30 a.m. ET to discuss the financial results and guidance, enhancing communication and transparency with investors.
- Live Webcast Opportunity: Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the company's website, ensuring timely access to key information for all stakeholders.
- Replay Access: Following the call, a replay will be available on the same website, further improving the accessibility and transparency of information for investors.
See More
Charles River Laboratories Under Investigation, Revenue Growth Expected to Decline by 400 Basis Points
- Investigation Launched: Former Louisiana Attorney General Charles C. Foti announces that Kahn Swick & Foti, LLC is investigating Charles River Laboratories for potential breaches of fiduciary duties to shareholders.
- Legal Action: Charles River and its executives are facing a securities class action lawsuit for failing to disclose material information, which could further impact the company's reputation and stock price.
- Revenue Growth Decline: The company disclosed in February 2023 that it suspended shipments of non-human primates from Cambodia due to a subpoena from the U.S. Department of Justice, leading to an expected revenue growth decline of 200 to 400 basis points, directly affecting annual financial performance.
- Compliance Risks: Kahn Swick & Foti's investigation will assess whether Charles River violated state or federal laws, and if confirmed, could lead to more severe legal consequences and financial losses.
See More
U.S. Stock Index Futures Rise as Bank Earnings Boost Market Sentiment
- Market Sentiment Rebound: U.S. stock index futures rose with S&P 500 futures up 0.42%, Nasdaq 100 futures up 0.56%, and Dow futures up 0.21%, indicating a boost in investor confidence driven by upbeat bank earnings and a tech rally.
- Treasury Yield Fluctuations: The U.S. 2-year Treasury yield fell to 3.57%, down 0.17%, while the 10-year yield edged lower to 4.17%, down 0.12%; conversely, the 30-year yield ticked up to 4.81%, adding 0.12%, reflecting mixed market expectations about future economic conditions.
- Premarket Trading Winners: In premarket trading, Ralph Lauren gained 1.74%, Baker Hughes rose 1.63%, and Robinhood Markets increased by 1.63%, indicating strong market performance that may attract further investor interest.
- Premarket Trading Losers: Conversely, Brown-Forman fell 4.33%, J.B. Hunt Transport Services dropped 4.19%, and Charles River Laboratories declined 3.13%, suggesting these companies are under market pressure, potentially impacting their short-term stock performance.
See More
Charles River Laboratories Upgraded to Overweight Rating
- Rating Upgrade: Charles River Laboratories (CRL) has received an overweight rating from analysts, reflecting market confidence in its future growth potential, which is expected to attract more investor interest.
- Market Expectations: Analysts have adjusted the average price target for CRL, indicating an optimistic outlook on the company's future performance, which could drive stock price increases and bolster investor confidence.
- Industry Position: As a key player in the biopharmaceutical sector, the upgrade in CRL's rating may enhance its competitiveness among peers, further solidifying its market leadership.
- Investor Reaction: The rating increase could lead to short-term stock price volatility, attracting more institutional investor attention, thereby increasing market liquidity and driving stock price appreciation.
See More
Charles River Laboratories Upgraded to Overweight Rating
- Rating Upgrade: Charles River Laboratories (CRL) has received an overweight rating from analysts, indicating a positive outlook for its future performance, which may drive stock price increases and attract more investor interest.
- Increased Market Confidence: The average price target for CRL has been raised by analysts, reflecting confidence in the company's continued growth in the biopharmaceutical sector, likely enhancing investor interest and trust in the firm.
- Optimistic Industry Outlook: With the rapid development of the biopharmaceutical industry, CRL, as a leading contract research organization, stands to benefit from overall industry growth, further solidifying its market position.
- Heightened Investor Attention: The rating upgrade may trigger increased attention from institutional investors, thereby enhancing CRL's market liquidity and shareholder base, promoting the company's long-term growth.
See More
Charles River Laboratories to Acquire $510M Assets and Appoint New Executive
- Acquisition Plan: Charles River Laboratories plans to acquire K.F. (Cambodia) Ltd. assets for approximately $510 million, a leading supplier of non-human primates, with the transaction expected to close in early Q1 2026, enhancing its supply capabilities in biomedical research.
- Earnings Outlook: The acquisition is projected to contribute about $0.25 to non-GAAP earnings per share in 2026 and $0.60 in 2027, despite K.F. not being expected to generate significant third-party revenue, thereby improving the company's overall profitability.
- Equity Acquisition: The company has also exercised its option to acquire the remaining 79% equity stake in PathoQuest SAS for approximately €51.6 million ($60 million), with the deal set to close by the end of Q1 2026, further solidifying its position in biopharmaceutical quality control testing.
- Executive Appointment: Charles River has appointed Namandjé Bumpus as Senior Vice President and Chief Scientific and Innovation Officer, aiming to strengthen its scientific leadership and innovation capabilities to drive future business growth.
See More
